Background Adult respiratory syncytial virus (RSV) vaccines are in the late stages of
development. A comprehensive synthesis of adult RSV burden is needed to inform public …

Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in
infants and the second most frequent cause of death during the first year of life. This highly …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Correlates of protection are key for vaccine development against any pathogen. In this paper
we summarize recent information about correlates for vaccines against dengue, Ebola …

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading
cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in …

In May 2023, the US FDA advisors endorsed Pfizer's pregnancy-administered vaccine
(branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection …

Respiratory syncytial virus (RSV) infection causes significant morbidity and mortality in
infants, immunocompromised individuals, and older individuals. There is an urgent need for …

Background Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory
infection (ALRI) in young children and is of considerable burden on healthcare systems. Our …

Respiratory syncytial virus (RSV) represents the main cause of acute respiratory tract
infections in children worldwide and is the leading cause of hospitalization in infants. RSV …

Respiratory infections pose a significant health problem among elderly individuals,
particularly during the COVID-19 pandemic. The increased mortality and morbidity rates …